TECENTRIQ sous-cutané sol inj 1875 mg/15 ml flac
7680692620019
CH-69262
L01FF05
07.16.1.
Reimbursement limitations:
TECENT.Lö.01
2L du CPNPC
Tecentriq est indiqué en monothérapie pour le traitement des patients atteints d’un …
1 / 2
google
Details
- Product number
- 6926201
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- atezolizumabum 1875 mg, hyaluronidasum humanum ADNr, histidinum, acidum aceticum 30 per centum, saccharum, polysorbatum 20, methioninum, aqua ad iniectabile ad solutionem pro 15 ml.
Articles (1)
TECENTRIQ subkutan 1875 mg/15ml, Injektionslösung zur subkutanen Anwendung
Injektionslösung zur subkutanen Anwendung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
1875.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 4221.55
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/11/2024
Authorization holder
Roche Pharma (Schweiz) AG
4058 Basel
Authorization information
- Swissmedic authorization number
- 69262
- Drug name
- TECENTRIQ subkutan, Injektionslösung
- Galenic form
- LSINJ
- ATC Code
- L01FF05
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 05/08/2024
- Authorization expiration date
- 04/08/2029
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- TECENTRIQ sous-cutané sol inj 1875 mg/15 ml flac
- Description (DE)
- TECENTRIQ subkutan Inj Lös 1875 mg/15 ml Durchstf
- Market launch
- 05/08/2024
- Narcotic (BTM)
- No